Shanghai Shenqi Pharmaceutical Investment Management (600613) Stock Overview
Operates as a pharmaceutical manufacturing holding investment company in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
600613 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥5.86 |
| 52 Week High | CN¥7.53 |
| 52 Week Low | CN¥5.37 |
| Beta | 0.64 |
| 1 Month Change | 0.69% |
| 3 Month Change | -6.24% |
| 1 Year Change | -4.25% |
| 3 Year Change | -23.70% |
| 5 Year Change | 29.36% |
| Change since IPO | -26.49% |
Recent News & Updates
Recent updates
A Look At The Fair Value Of Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. (SHSE:600613)
Dec 24
There May Be Reason For Hope In Shanghai Shenqi Pharmaceutical Investment Management's (SHSE:600613) Disappointing Earnings
Nov 06Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd.'s (SHSE:600613) 26% Share Price Surge Not Quite Adding Up
Oct 21Why Shanghai Shenqi Pharmaceutical Investment Management's (SHSE:600613) Earnings Are Better Than They Seem
May 06Investor Optimism Abounds Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. (SHSE:600613) But Growth Is Lacking
Apr 17Shareholder Returns
| 600613 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -3.3% | -0.5% | 2.7% |
| 1Y | -4.2% | 12.9% | 35.3% |
Return vs Industry: 600613 underperformed the CN Pharmaceuticals industry which returned 12.9% over the past year.
Return vs Market: 600613 underperformed the CN Market which returned 35.3% over the past year.
Price Volatility
| 600613 volatility | |
|---|---|
| 600613 Average Weekly Movement | 5.3% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in CN Market | 9.9% |
| 10% least volatile stocks in CN Market | 4.1% |
Stable Share Price: 600613 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600613's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 1,266 | Feng Bin | www.gzsq.com |
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd., together with its subsidiaries, operates as a pharmaceutical manufacturing holding investment company in China. The company engages in the research and development, and production of anti-tumor, cardiovascular, cerebrovascular, rheumatism bone pain, tonic and sedative, cold and cough, anti-fungal, gynecology, and other treatment fields. Its products include prescription drugs and OTC products, including products include sodium cantharidate vitamin B6 injection, sodium cantharidin injection, loquat cough granules, strong loquat dew, loquat cough capsules, jinwu gutong capsules, coral ringworm net, jingwu capsules, quantianma capsules, yindan xintai pills, etc. The company was founded in 1990 and is based in Shanghai, China.
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. Fundamentals Summary
| 600613 fundamental statistics | |
|---|---|
| Market cap | CN¥2.99b |
| Earnings (TTM) | CN¥62.34m |
| Revenue (TTM) | CN¥1.88b |
Is 600613 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600613 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.88b |
| Cost of Revenue | CN¥1.04b |
| Gross Profit | CN¥845.43m |
| Other Expenses | CN¥783.10m |
| Earnings | CN¥62.34m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Apr 30, 2026
| Earnings per share (EPS) | 0.12 |
| Gross Margin | 44.89% |
| Net Profit Margin | 3.31% |
| Debt/Equity Ratio | 7.9% |
How did 600613 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/20 21:25 |
| End of Day Share Price | 2026/04/20 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.